Metabotropic glutamate receptors are family C G-protein-coupled receptors. They form obligate dimers and possess extracellular ligand-binding Venus flytrap domains, which are linked by cysteine-rich domains to their 7-transmembrane domains. Spectroscopic studies show that signalling is a dynamic process, in which large-scale conformational changes underlie the transmission of signals from the extracellular Venus flytraps to the G protein-coupling domains-the 7-transmembrane domains-in the membrane. Here, using a combination of X-ray crystallography, cryo-electron microscopy and signalling studies, we present a structural framework for the activation mechanism of metabotropic glutamate receptor subtype 5. Our results show that agonist binding at the Venus flytraps leads to a compaction of the intersubunit dimer interface, thereby bringing the cysteine-rich domains into close proximity. Interactions between the cysteine-rich domains and the second extracellular loops of the receptor enable the rigid-body repositioning of the 7-transmembrane domains, which come into contact with each other to initiate signalling.
Metabotropic glutamate receptors (mGlus) are G-protein-coupled receptors (GPCRs) that are activated by the excitatory neurotransmitter l-glutamate 1, 2 . Family C receptors are unusual in that, as well as the GPCR-defining 7-transmembrane (7TM) domain, they possess relatively large amino-terminal extracellular domains (ECDs) that form obligate dimers and contain the orthosteric ligand-binding sites. In the mGlu subfamily, the ECD is composed of a conserved, ligand-binding Venus flytrap (VFT) domain and a cysteine-rich domain (CRD). The VFT is connected to the 7TM domain by the CRD, which provides a semi-rigid linker between the ligand-binding and the 7TM (signalling) domains 2 . Previous structural work on VFTs in isolation has shown that agonist binding leads to two major structural changes in the conformation of the dimer. The first is a closure of the two VFT lobes 3 . Signalling studies in live cells have suggested that VFT closure is essential for activation-closure of one lobe is sufficient for signalling, whereas closure of both lobes is necessary for full efficacy 4 . The second conformational change involves an intersubunit reorientation that brings the CRDs of the adjacent VFTs into close proximity to each other 3 (Fig. 1a ). Fluorescence resonance energy transfer studies of full-length receptors in live cells have shown that activation probably depends on sequential inter-and intrasubunit conformational changes 5 . The 7TM domain of mGlu receptors is the binding site of various non-endogenous allosteric ligands that can modulate signalling either alone or in conjunction with orthosteric ligands, thereby acting as positive allosteric modulators (PAMs) or negative allosteric modulators (NAMs). Crystal structures of the mGlu1 6 and mGlu5 7TM [7] [8] [9] domains show that the allosteric ligand-binding pockets largely overlap with those of orthosteric ligands in family A GPCRs 10 . Isolated 7TM domains also function similarly to rhodopsin-like GPCRs, with PAMs acting similarly to agonists at family A receptors 11 . It is noteworthy that many PAMs that are normally silent in full-length receptors act as full agonists at isolated 7TM domains 12 , which suggests that the conformation of the extracellular domains of the mGlu receptor is a critical regulator of activation and signalling. To understand how agonist binding at the VFT is relayed over 120 Å to the intracellular G-protein-coupling region of the 7TM domain, we used a combination of cryo-electron microscopy (cryo-EM), X-ray crystallography and biochemical assays to obtain structures of the mGlu5 dimer in the inactive and active states.
Structures of active-conformation-stabilizing ligands
For structural studies, we sought to complement orthosteric and allosteric small-molecule ligands with a nanobody-a single-chain camelid antibody-that could further stabilize the receptor in one conformation 13 . We therefore immunized a llama with full-length mGlu5, and after an initial screen for receptor binding and function we selected one nanobody, termed Nb43, on the basis of its ability to potentiate orthosteric agonist binding. Whereas the orthosteric endogenous agonist l-glutamate displaces the orthosteric analogue [ Table 1) . Despite previous conflicting reports [14] [15] [16] , CDPPB was found to increase the affinity and the maximal binding capacity of [ Table 2) . Functionally, l-glutamate and l-quisqualate induce G q coupling, which in turn leads to intracellular calcium release (Fig. 1c, Supplementary  Table 3 ). During initial functional testing of Nb43 and CDPPB, both ligands seemed to potently activate mGlu5 (Fig. 1c) . Because high receptor expression levels 17 -as well the presence of minute amounts of glutamate in the assay medium-are known confounders of these Article reSeArcH assays 18 , we overexpressed the neuronal excitatory amino acid transporter 3 (EAAT3) together with lower levels of mGlu5 that are similar to those observed in cortical astrocytes 16 (Supplementary Table 5 ). Under these conditions, Nb43 had almost no intrinsic activity and that of CDPPB was considerably reduced (Fig. 1d) . Nonetheless, Nb43 and CDPPB functionally potentiated each other ( Supplementary Fig. 1 ) as well as l-quisqualate (Fig. 1e , f, Supplementary Table 3), which suggests that they act as PAMs to further stabilize an active signalling complex.
To understand the binding mode of Nb43 and its cooperativity with orthosteric agonists, we solved the X-ray structures of the aminoterminal domain of mGlu5 in complex with the nanobody both in the presence and in the absence of l-quisqualate (Fig. 2) . Our construct extends through the CRD of mGlu5; however, in the apo state this region has weak electron density protruding diametrically opposite to the CRD of the second monomer, thereby assuming an orientation that is incompatible with a membrane-anchored receptor dimer (Extended Data Fig. 1a ). Nb43 binds the apex of the VFT domain (Fig. 2a) , with most contacts occurring between the complementarity determining regions 2 and 3 (CDR2 and CDR3) of the nanobody and two loops formed by residues 345-357 and residues 365-375 on mGlu5, respectively (Fig. 2a, b , Extended Data Fig. 1b, c) . The binding interface of Nb43 is defined by two tryptophan residues (Trp107 and Trp110) that fold CDR3 against the core regions of the nanobody and orient it for binding within a groove at the apex of the VFT (Extended Data  Fig. 1d ). The majority of interactions between Nb43 and mGlu5 are polar (Fig. 2b) and involve residues that are poorly conserved among mGlu receptor subtypes (Extended Data Fig. 1c) , which suggests that Nb43 would be a subtype-selective PAM of mGlu5. Overall, the architecture of this VFT dimer is that of an ' Aoo' (active open-open) form 19 , which has been observed very infrequently in crystal structures of antagonist-bound ECDs of mGlu1 (Protein Data Bank (PDB): 3SK9) and mGlu2 (PDB: 5KZN) 20 . The Aoo form is characterized by the close proximity of the VFT bottom lobes despite the flytraps being open (Fig. 2d, middle) .
We also solved the crystal structure of the mGlu5 extracellular domain in the presence of Nb43 and l-quisqualate at a resolution of 3.75 Å. Although we do observe strong CRD density, our resolution limited us to mostly backbone modelling of this region (Extended Data  Fig. 1e ). We also modelled only one nanobody in the dimer, although we observe diffuse, positive density at the expected location of the second nanobody. Overall, this structure looks almost identical to that of the mGlu5 VFT in complex with glutamate (PDB: 3LMK) (root mean squared deviation, r.m.s.d., of 0.5 Å), and we observe the canonical agonist-bound ' Acc' (active closed-closed) VFT conformation (Fig. 2c) that, similar to the Aoo form presented above, is typified by a close proximity between VFT bottom lobes (Fig. 2c, d ). Compared to the Nb43-apo structure, the binding of l-quisqualate not only leads to closure of the VFT lobe around the ligand but also results in the establishment of a defined intersubunit CRD interaction interface (Fig. 2c, d ). This close apposition of the CRDs is consistent with observations that the introduction of intersubunit CRD crosslinks leads to constitutive activity in mGlu receptors 21 . Despite extensive optimization, crystals of a full-length construct of mGlu5 bound to the F-MTEB analogue 3-fluoro-5-(2-(2-(fluoromethyl)thiazol-4-yl)ethynyl)benzonitrile 22 (FFMTEB), a potent and selective NAM, diffracted to only 4 Å resolution and lacked interpretable electron density in the transmembrane domain. Nonetheless, we were able to build and refine a model of the VFT and parts of the CRD domains (Fig. 2d , left) in their apo form. A comparison of this structure with that of the Nb43 complex and the complex with both Nb43 and l-quisqualate elucidates the structural transitions that underlie activation at the extracellular domain of mGlu5. Agonist binding reorients the dimer interface from the resting to the active state, as measured by a reduced B-C helix angle 3 , and leads to a conformation in which the VFT bottom lobes are located proximally to each other. The CRDs are Article reSeArcH accordingly repositioned to relay this conformational change towards the membrane (Fig. 2d) .
Cryo-EM structures of full-length mGlu5
To better understand activation in the full-length mGlu5, we used cryo-EM to obtain structures of the receptor dimer in both the inactive and the active states (Extended Data Fig. 2b-f) . Initial efforts to obtain the structure of detergent-reconstituted mGlu5 in the inactive (apo) state revealed a large population of receptors with split micelles that each contained one of the 7TM domains, which suggests that the inactive state is characterized by a lack of strong interactions between the transmembrane domains (Extended Data Fig. 2a ). Given the possibility that the 7TM domain separation is a result of detergent solubilization, we reconstituted mGlu5 into nanodiscs and obtained a cryo-EM map of the full-length receptor at an overall resolution of 4.0 Å (Fig. 3a , Extended Data Figs. 2-4 ). This map enabled us to build a full-length apo-state model of mGlu5 including unambiguous placement of all transmembrane helices, aided in part by the availability of crystal structures of all components 7, 23 (Extended Data Fig. 5a, b) . The inactive conformation of mGlu5 involves a single interaction interface at the apex of the VFT domain (Fig. 3a, Extended Data Fig. 6, top) . This interface, mostly formed by hydrophobic residues, is further stabilized by the conserved disulfide bond between the Cys129 residues of each subunit; however, this disulfide bond is not required for either dimer formation or signalling 24 . We note that the cryo-EM map lacks density for residues 123-135, and therefore we cannot confidently model the position of the disulfide. Although our crystal structure of apo mGlu5 only allowed for building of the ECD (as discussed above), its observed conformation is in the context of a full-length receptor that is restrained by its 7TM domains in detergent. It therefore enables a direct comparison with the cryo-EM structure, which includes density for all domains. Both structures show nearly identical ECD conformations, as evidenced by a backbone r.m.s.d. of 0.9 Å (Extended Data Fig. 7a) , with the conformation of the CRDs indicating well-separated 7TM domains.
We prepared a stable, detergent-solubilized mGlu5 in the presence of l-quisqualate, CDPPB and Nb43, enabling us to obtain a cryo-EM map of an active-state complex at a global resolution of 4.0 Å (Fig. 3b) . The map shows well-resolved features in the VFT and the CRD domains (Extended Data Figs. 4 , 5c-f) and, despite the lower local resolution in the transmembrane portion, it enables unambiguous placement of transmembrane helices (Fig. 3b, Extended Data Figs. 4, 5g, h ). The active state of mGlu5 is very compact, with interactions between subunits at each of the VFT, CRD and 7TM domains (Fig. 3b, Extended Data Fig. 6, bottom) . This is further demonstrated by a substantially buried surface area of 2,160 Å 2 compared to 630 Å 2 in the inactive state (Extended Data Fig. 6 ).
Activation leads to compaction of the mGlu5 dimer
The cryo-EM structures of full-length mGlu5 in active and inactive states complement our crystallographic observations of the ECDs, and explain how ligand binding at the ECD is relayed to the 7TM domain. Globally, agonist binding leads to a substantial compaction of the mGlu receptor dimer (Fig. 3c, d, Supplementary Video 1) . In its apo state, the mGlu5 VFT adopts an 'Roo' (resting open-open) conformation with a bottom lobe separation of 35 Å at Asp233, whereas in the agonist-bound Acc conformation, this distance is reduced to 21 Å. In both states, the CRDs extend almost straight down from the C terminus of the VFT towards the membrane. In the inactive state, the average separation at Glu527 of the CRD is 43 Å, whereas this distance is reduced to 10 Å in the active state. The 7TM domains are completely separated in the inactive state; a backbone distance of 21 Å is observed between the TM5 helices of the two protomers, which are the most proximal transmembrane helix pair (Fig. 3c) . In the active state the 7TM domains show a strong interaction along the TM6 helices, with a backbone separation distance of 6 Å at Ile791 (Fig. 3d) .
The individual 7TM domains of both apo-and agonist-bound mGlu5 align well with each other and are almost identical in conformation to thermostabilized NAM-bound crystal structures [7] [8] [9] of the mGlu5 transmembrane domain in isolation (r.m.s.d. of 1.4 Å) (Extended Data Fig. 7c, d ). Although the local resolution of the 7TM domains in both of our maps precludes unambiguous assignment of the state of the ligand at the allosteric site, the full agonist l-quisqualate appears unable to stabilize an active conformation within the 7TM bundle. This observation is not entirely unexpected, as most family A receptors do not fully adopt their active conformation in the absence of intracellular stabilizers such as G proteins 25, 26 . The structure of an active family C 7TM domain therefore remains unknown.
Agonist-induced structural changes are thought to be in part regulated by a hydrophobic patch of residues formed by the B and C helices at the apical surface of the VFT (Fig. 4a, b) . Notably, this hydrophobic patch is the only interface that is conserved between apo and active mGlu5 (see above, Extended Data Fig. 6 ). Single-molecule fluorescence resonance energy transfer studies in mGlu2 showed that mutations that weaken this interface not only lead to increased glutamate affinity, but also to increased occupancy of the active conformation, even in the absence of agonists 27 . Our structures complement these results. 
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Compared to the tight interactions of the apo state (Fig. 4e, f ), the active state shows a more open interface ( Fig. 4g, h ). Because the loops that immediately precede both the B and C helices contain residues that are important for ligand recognition, the binding of an agonist in the VFT may trigger relaxation of the B-C intersubunit interface, which releases its constraint upon activation. A further network of polar interactions at the apical surface of the B helices helps to stabilize the active conformation. Notably, Arg114 releases its interaction with Glu111 ( Fig. 4c ) of the complementary subunit to engage the more distal Glu121 (Fig. 4d) , and thus helps to maintain the acute intersubunit B-helix angle that defines the active state. Unexpectedly, we also observed a potential interaction between Arg29 of Nb43 and Glu124 on the B helix of the protomer opposite to its major binding interface, which may provide a structural explanation for the allosteric properties of Nb43 (Fig. 4d) . We note, however, that Nb43 alone cannot stabilize the active receptor conformation and the CRD interface. This interpretation is supported by cryo-EM analysis of full-length mGlu5 with bound Nb43 in the absence of an orthosteric ligand, which shows a dimer configuration that is very similar to the apo state (Extended Data Fig. 3b ). Consistent with this finding, our molecular dynamics simulations show that Nb43 binding alone does not induce closure of the VFTs, but restricts them from opening to the extent of the fully inactive conformation (Extended Data Fig. 8 ).
Activation of mGlu5 reorients the 7TM interface
Although dimeric associations between normally monomeric family A receptors have been observed in crystal structures, they show varied interaction interfaces and their physiological relevance is debated [28] [29] [30] . Previous work on mGlu1 and mGlu2 has led to contradicting models of the relative intersubunit transmembrane interface. Whereas the crystal structure of the mGlu1 7TM domain bound to the negative modulator 4-fluoro-N-(4-(6-(isopropylamino)pyrimidin-4-yl) thiazol-2-yl)-N-methylbenzamide (FITM) suggested a sterol-rich TM1 interface 6 , crosslinking studies of mGlu2 proposed an inactive state mediated by TM4 and TM5 that transitions to a TM6-driven interface in the presence of an agonist 31 . Our structures revealed that, in addition to moving closer to each other, there is a 20° rotation of each 7TM upon activation ( Fig. 5a -d, Extended Data Fig. 9a, b) . Consequently, the TM1-TM1 distance decreases from around 70 Å in the inactive state to around 43 Å in the active state, as previously proposed 31 ( Fig. 5c, d ). More importantly, the propagation of structural changes leads to a TM6-TM6 interface that appears to be a hallmark of activation (Fig. 5d ). This 'active' TM6 interface was confirmed by the introduction of a cysteine-mediated crosslink at the extracellular face of TM6 (I791 6.56 C after removal of the crosslink in the VFT(C129A)) (Extended Data TM1   TM2   TM3   TM4   TM5   TM6  TM7 TM7   TM1   TM2   TM3   TM4   TM5   TM6   TM7 TM7   TM1   TM2   TM3   TM4   TM5   TM6   TM1   TM2   TM3   TM4   TM5   TM6   TM7 TM7   TM7 TM7 Cysteine-rich domain TM1 TM1 TM2 TM2   TM3 TM3   TM4 TM4  TM5 TM5  TM6 TM6   TM7 TM7  TM1 TM1  TM5 TM5   TM1 TM1   TM2 TM2   TM3 TM3   TM4 TM4  TM6 TM6  TM7 TM7  TM5 TM5   TM6 TM6   TM7 TM7  TM3 TM3  TM3 TM3   TM2 TM2   0 56 is shown as a sphere for reference. e, Crosslinking of TM6 and subsequent re-establishment of the homodimer after removal of the crosslink in the VFTs by a C129A mutation is less efficient when the receptor is bound to a NAM (MPEP; yellow bars). f, A TM6 crosslinked mGlu5 is constitutively active (top) but responds to a 7TM negative modulator (bottom). Bars in e represent mean ± s.e.m. from eight independent experiments. Statistics were performed using repeated measures oneway ANOVA followed by Tukey's multiple comparisons test and indicated P values were adjusted to account for multiple comparisons. Data in f represent mean ± s.e.m. from five (top) and six (bottom) independent experiments performed in duplicate.
Article reSeArcH C129A, I791 6.56 C and C129A + I791 6.56 C mutants are comparable to those of the wild type ( Supplementary Fig. 3 ). The C129A + I791 6.56 C mutant was found to spontaneously undergo dimer formation, but with higher efficiency in the absence of the NAM 2-methyl-6-(phenylethynyl)pyridine (MPEP) (Fig. 5e, Extended Data Fig. 9d ). The TM6-crosslinked mGlu5 is constitutively active (Fig. 5f, top) and is not responsive to orthosteric agonists, a finding that was previously observed in an I 6.56 C TM6-locked mGlu2 31 . Notably, despite being locked in an active conformation, the I791C mutant receptor is still responsive to the 7TM NAM MPEP, which inhibited signalling in a dose-dependent manner (Fig. 5f , bottom) albeit with lower potency. The fact that a 7TM NAM is able to overcome the constitutive activity of the TM6-locked construct strongly suggests that the activation profile of mGlu receptors requires both inter-and intrasubunit conformational changes 5 .
Propagation of orthosteric activation signals
Our cryo-EM structures of both active and inactive mGlu5 reveal an unexpected intrasubunit interaction between the CRD and extracellular loop (ECL)2 of the 7TM domain (Fig. 6a) . A first hint into the potential role of ECL2 in aiding signal transduction came from the crystal structure of the mGlu1 7TM domain 6 , which featured an extended ECL2 hairpin that projected outwards towards TM1 and the space in which the CRD was predicted to reside 33 . Notably, the conformation of ECL2 in our full-length structure is almost identical to that of the mGlu1 7TM domain. Despite the limited resolution of our maps, we can model two interaction interfaces using previous structural information as a guide. Interface 1 involves a short hydrophobic interface between residues 729-731 of ECL2 and residues 568-571 at the CRD-TM1 boundary (Fig. 6a) . Interface 2 encompasses residues 725-727 at the apical loop of the ECL2 β-hairpin and a composite interface composed of residues Glu539 and Trp557 of the CRD (Fig. 6a) . In particular, the chemistry and proximity of Arg727 in ECL2 enables it to potentially form interactions with either Glu539 or Trp557 in the CRD, through ionic or cation-π interactions. To further validate the role of this interface in the propagation of signals to the 7TM domain, we generated ECL2 mutants of full-length mGlu5 as well as of a truncated mGlu5 construct that encodes the 7TM domain alone. Previous work has shown that an isolated mGlu5 transmembrane domain functions similarly to rhodopsin-like receptors, with PAMs and NAMs acting analogously to orthosteric agonists and antagonists at family A GPCRs 11 . Deletion of residues Ile726 and Arg727 at the apex of ECL2 markedly reduces the orthosteric agonist action of l-glutamate and (S)-3,5-dihydroxyphenylglycine ((S)-3,5-DHPG) in the full-length receptor (Fig. 6b, Supplementary Fig. 2, Supplementary Table 4) ; however, it has only a small effect on the action of CDPPB in the full-length receptor (Fig. 6c, Supplementary Table 4) , and no effect on CDPPB activation of the 7TM domain alone (Fig. 6d, Supplementary Table 4) . We note that surface expression levels-as well as total expression levels-of the ECL2-I726-R727 deletion mutant were comparable to those of the wild type, but that further truncation of ECL2 compromised surface expression ( Supplementary Fig. 3 ). Deletion of I726 and R727 in ECL2 did not affect the respective constitutive activities of the fulllength receptor and 7TM domain constructs ( Supplementary Fig. 2 ). The reduction in maximal signalling response with orthosteric agonists of the ECL2-I726-R727 deletion mutant suggests that ECL2 may serve as a rigid fulcrum that aids in the propagation of agonist-induced conformational changes at the VFT to the signalling domain in the membrane. It is likely that, in the absence of this ECL2 interaction, the loop at the boundary of the CRD and TM1 does not have the rigidity to relay the conformational change to the 7TM domain, and is therefore unable to direct the structural rearrangements that lead to the formation of the active TM6 interface.
Discussion
The combination of our in vitro data, crystal structures and cryo-EM structures of mGlu5 enable us to propose a structural framework for mGlu5 activation. Agonists stabilize a compact VFT conformation that is characterized by a relatively small intersubunit bottom-lobe distance. The proximity of these bottom lobes is propagated through the CRDs to the 7TM domains, which reorient to form a TM6-mediated interface that is signalling-competent. The geometry of this structural rearrangement is crucial, as only certain intersubunit CRD crosslinks have been shown to increase receptor activity 5 . Similar rearrangements have been observed in other class C GPCRs, suggesting that a conformational transition by which the TM domains come into close proximity may be a hallmark of activation in this family 34, 35 . We identified ECL2 as necessary to relay the agonist-induced conformational changes to the 7TM domain, as it provides a second, rigid attachment point between the ECD and transmembrane domains. We therefore propose that the ECL2-CRD interaction is the structural basis for the allostery that has been observed between the ECD and the 7TM domain 36, 37 . Although our results do not fully explain how agonist binding at the VFT leads to G protein coupling and activation, they do support a model in which both inter-and intrasubunit rearrangements are required for full activity 5 . This work addresses the first of these conformational changes. Further studies are required to elucidate the mechanism by which the establishment of a TM6-TM6 interface leads to transmembrane domain rearrangements that enable G protein coupling and signalling.
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MEthodS
No statistical methods were used to predetermine sample size. The experiments were not randomized and the investigators were not blinded to allocation during experiments and outcome assessment. Purification of mGlu5 ECD. A construct encoding residues 21-569 of wild-type human mGlu5 followed by a hexahistidine tag was cloned into the insect cell secretion vector pACGP67 and used to generate Baculovirus using the BestBac method (Expression Systems). Hi-Five (Trichoplusia ni) cells were infected with baculovirus at a density of 3.5 × 10 6 cells per ml for 72 h at 27 °C. Cells were removed from the medium by centrifugation at 3,360g, at which point the medium was quenched of chelating agents by addition of 1 mM NiCl 2 and 5 mM CaCl 2 with rapid stirring at 25 °C for 1 h. Precipitates were removed from the medium by centrifugation at 3,360g. The pH of the medium was balanced by the addition of Tris pH 8.0 (to a final concentration of 50 mM) before loading over 5 ml of Ni-NTA resin. Resin was washed in 500 mM NaCl, 20 mM HEPES pH 7.5 and 20 mM imidazole, then in 100 mM NaCl, 20 mM HEPES pH 7.5 and 20 mM imidazole. Protein was eluted in 100 mM NaCl, 20 mM HEPES pH 7.5 and 250 mM imidazole, after which fractions containing ECD were pooled, and the His tag was removed by the addition of carboxypeptidase A and B during overnight dialysis into 100 mM NaCl, 20 mM HEPES pH 7.5 at 4 °C. Contaminants and uncleaved protein were separated by flowing over Ni-NTA resin and the flow-through was collected. The protein was finally purified by size-exclusion chromatography on a Superdex 200 10/30 column in 100 mM NaCl with 20 mM HEPES pH 7.5. Monomeric fractions were pooled and concentrated to 30 mg ml −1 and flash-frozen in liquid nitrogen. Purification of Nb43 for signalling studies and crystallography. Nb43 was cloned into a modified pE-SUMO vector containing a PelB leader sequence and AAA linker in front of the SUMO fusion tag. Transformed BL21 Escherichia coli were grown to an optical density at 600 nm (OD 600 ) of about 0.6 at 37 °C and induced with 1 mM IPTG, and transferred to 25 °C shakers in which induction was allowed to run overnight. Bacteria were collected by centrifugation and frozen. Nb43 was purified from the periplasm using established protocols. In brief, cells were thawed in two volumes SET buffer (0.5 M sucrose, 0.5 mM EDTA, 0.2 M Tris pH 8.0) and stirred until homogenized before the addition of 3 volumes of 25 °C Milli-Q water with rapid stirring for 45 min to release periplasmic contents. Cell debris was removed by centrifugation at 24,400g for 20 min. Before loading over Ni-NTA resin, 100 mM NaCl and 10 mM MgCl 2 were added to provide ionic strength and to quench EDTA, respectively. After loading the quenched sample, resin was washed in 500 mM NaCl, 20 mM HEPES pH 7.5 and 20 mM imidazole, then in 100 mM NaCl, 20 mM HEPES pH 7.5 and 20 mM imidazole. Protein was eluted in 100 mM NaCl, 20 mM HEPES pH 7.5 and 250 mM imidazole, fractions containing SUMO-Nb43 were pooled, and His-SUMO tags were removed by the addition of ULP1. Imidazole was removed by overnight dialysis into 100 mM NaCl, 20 mM HEPES pH 7.5 at 4 °C. Contaminants and uncleaved protein were separated by flowing over Ni-NTA resin and the flow-through was collected. Nb43 was finally purified by size-exclusion chromatography on a Superdex 200 10/30 column in 100 mM NaCl with 20 mM HEPES pH 7.5. Monomeric fractions were pooled and concentrated to 98 mg ml −1 (around 3 mM) and flash-frozen in liquid nitrogen. Nb43 purified in this manner was used for both structural and pharmacological studies. Crystallization of the apo ECD in complex with Nb43 and data collection. mGlu5 ECD was incubated with 1.2 molar excess Nb43 for 30 min at 25 °C and excess Nb43 was removed by size-exclusion chromatography on a Superdex 200 10/30 column in 100 mM NaCl with 20 mM HEPES pH 7.5. Fractions containing complex were pooled and concentrated to 20 mg ml −1 and flash-frozen in liquid nitrogen.
Initial crystallization hits were identified in around 30% of conditions in commercial screens, and a refined condition containing 18-20% PEG 3350, 0.15 M potassium nitrate, with 1% benzamidine gave final crystals. These crystals were cryoprotected in reservoir solution + 25% glycerol and frozen in liquid nitrogen.
Data were collected on BL12-2 at SSRL at 100 K, processed using XDS 38 and scaled using AIMLESS 39 in the CCP4 40 suite. Phases were obtained by molecular replacement, using individual top and bottom VFT lobes from a structure of the mGlu5 VFT bound to glutamate (PDB: 3LMK). A homology model of Nb43 was generated using Swiss-Model 41 and manually placed in positive density after refinement to the VFT alone. The model was iteratively refined using PHENIX 42 and manually in Coot 43 and showed good stereochemistry, with 94.95% of residues in Ramachandran favoured zones, 4.97% in allowed zones and 0.08% outliers. Crystallization of the ECD in complex with quisqualate and Nb43. mGlu5 ECD in complex with Nb43 was incubated with a tenfold molar excess of l-quisqualic acid (Tocris) for 30 min at 25 °C and initial crystallization hits were identified using commercial screens. Crystals reproducibly emerged in 100 mM NaCl with 20% PEG species at a range of pH values. Final crystals were grown in 100 mM NaCl, 50 mM ADA buffer pH 7.0 and 20% PEG 4000. Crystals were cryoprotected in reservoir solution plus 25% glycerol and frozen in liquid nitrogen.
Data were collected on Beamline 23 IDB at the Advanced Photon Source (APS) at Argonne National Laboratories and processed using XDS 38 and AIMLESS 39 from the CCP4 40 package. Phases were obtained by molecular replacement using a structure of the mGlu5 VFT bound to glutamate (PDB: 3LMK), and nanobodies were placed using the structure of the apo ECD in complex with Nb43. Model building was performed manually in Coot 43 and refined using PHENIX 42 and BUSTER 44, 45 . The final model showed good stereochemistry, with 94.66% of residues in Ramachandran favoured zones, 5.34% in allowed zones and 0% outliers. Expression, purification and crystallization of full-length mGlu5 bound to NAM FFMTEB. The haemagglutinin (HA) signal peptide, followed by a Flag epitope tag (DYKDDDD) and a three-alanine linker, was added to the N terminus of unmodified human mGlu5 (21-865) with a hexahistidine tag at the C terminus. This construct was cloned into the pFastBac1 sf9 expression vector and recombinant baculovirus was prepared using the Bac-to-Bac baculovirus expression system (Invitrogen). SF9 insect cells were infected with the virus at a cell density of 3.5 × 10 6 cells per ml and grown for 48 h at 27 °C with gentle rotation. Cells were collected by centrifugation, and lysed by resuspension in hypotonic buffer containing 10 mM Tris at pH 7.8 and 1 mM EDTA with protease inhibitors followed by homogenization. The cell membrane pellet was collected by centrifugation and was solubilized with 1% (w/v) n-dodecyl-β-d-maltoside (DDM) (Anatrace), 0.1% (w/v) cholesteryl hemisuccinate (CHS) (Steraloids), 0.2% (w/v) sodium cholate (Anatrace), 750 mM NaCl, 30% glycerol, iodoacetimide (2 mg ml −1 ), protease inhibitor and 10 μM FFMTEB (compound 3 in ref. 22 ) (a gift from H. Lundbeck). FFMTEB (3-fluoro-5-(2-(2-(fluoromethyl)thiazol-4-yl) ethynyl)benzonitrile) is a fluorinated analogue of F-MTEB with exceptionally high affinity and selectivity for mGlu5. The supernatant was isolated and incubated with anti-Flag M1 affinity resin (Sigma) overnight at 4 °C. The resin was washed with 0.1% (w/v) DDM, 0.01% (w/v) CHS, 500 mM NaCl, 10% glycerol and 10 μM FFMTEB, followed by 0.1% (w/v) lauryl maltose neopentyl glycol (LMNG), 0.01% (w/v) CHS, 150 mM NaCl and 10 μM AF57974 buffer to exchange the detergent. mGlu5 bound to FFMTEB was eluted in 30 mM HEPES pH 7.5, 150 mM NaCl, 0.01% (w/v) MNG, 0.01% (w/v) CHS, 200 μg ml −1 Flag peptide, 5 mM EDTA and 10 μM FFMTEB. The protein was concentrated in a 50-kDa cutoff Vivaspin (Millipore) filter and run on a Superdex 200 size-exclusion column (GE Healthcare).
Purified mGlu5 receptor was concentrated to 20 mg ml −1 and crystallized using the vapour-phase diffusion method. Protein was mixed with precipitant solution at a 1:1 ratio in sitting drops, using a Gryphon Crystallography Robot (Art Robbins Instrument) for setups. The crystals that were used for data collection were grown in 15% PEG 3350 (w/v), 0.2 M sodium cacodylate pH 6.5 at 20 °C in a 24-well plate (Hampton Research). Crystals were cryoprotected by adding glycerol in a stepwise manner to reach a final concentration of 30%, and then flash-frozen in liquid nitrogen. X-ray data collection, processing and structure determination of full-length mGlu5 bound to the NAM FFMTEB. X-ray diffraction data were collected at APS at GM/CA beamline 23ID-D and 23ID-B. Even though the crystals were of sufficient size (>0.2 mm), usually only a particular small region yielded suitable diffraction. The entire crystal was therefore first screened by rastering using a 40 μm × 40 μm-beam with fivefold attenuation and 0.5-s exposure. Regions that contained the strongest diffraction were then sub-rastered using a 20-μm collimated beam with fivefold attenuation. Data were then collected with the 20-μm beam using two-to fivefold attenuation with 1-2-s exposures and 0.2-degree oscillations. Owing to radiation damage, data was collected in wedges of 5-25 degrees before moving onto either a different site on the crystal or a new crystal. Diffraction data were processed using XDS 38 and statistics are summarized in Extended Data Table 1 . The structure was solved by molecular replacement using Phaser with the mGlu5 VFT domain structure in an open conformation (from the structure of apo ECD in complex with Nb43, but with Nb43 removed) as the search model. The resulting model was completed by iterative refinement in PHENIX 42 , Refmac 46 and BUSTER 44, 45 and manual building with Coot 43 . MolProbity 47 was used for structure validation, and figures were prepared using PyMOL (Schrödinger). Final refinement statistics are reported in Extended Data Table 1 . In short, despite the limited resolution, we were able to refine a model with excellent stereochemistry (94% Ramachandran favoured, 5.9% Ramachandran allowed and 0.1% outliers) and well-defined electron density for the main chain and the majority of the side chains. Liposome reconstitution and llama immunization. The mGlu5 full-length receptor was purified as described above. The resulting receptor was reconstituted into phospholipid vesicles composed of 1,2-dioleoyl-sn-glycerol-3-phosphocholine (DOPC, Avanti Polar Lipids) and lipid A (Avanti Polar Lipids) in a 10:1 ratio at a final receptor concentration of 1 mg ml
. The reconstituted receptor was flash-frozen in liquid nitrogen in 100 ug aliquots for llama immunization. One llama was immunized over 6 weeks with 0.25 mg of liposome-reconstituted mGlu5. Peripheral blood lymphocytes were isolated from the llama to extract total RNA, prepare cDNA and construct a nanobody phage-display library as previously described 48 . Animal studies were performed under ethical guidelines outlined by
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European Union animal welfare legislation and a local ethical committee for use of laboratory animals of the Vrije Universiteit Brussels. Preparation of mGlu5 membranes for cryo-EM studies. The HA-Flag-human mGlu5 (21-865) construct described above was used to infect Spodoptera frugiperda Sf9 cells at a density of 4 million cells per ml in the presence of 3-((2-methyl-4-thiazolyl)ethynyl)pyridine (MTEP). Infection continued for 60 h at 27 °C with rotation at 130 r.p.m., at which point cells were collected by centrifugation and stored at −80 °C. Membranes were prepared following established protocols. In brief, collected cell pellets were thawed and lysed in hypotonic buffer (10 mM HEPES pH 7.5, 1 mM EDTA with 160 μg ml −1 benzamidine and 2.5 μg ml −1 and 10 μM MTEP). Cytoplasmic contents were separated by centrifugation, and cell remains were resuspended in a high salt buffer composed of 1 M NaCl, 20 mM HEPES pH 7.5, 160 μg ml −1 benzamidine, 2.5 μg ml −1 leupeptin and 10 μM MTEP) using a tissue shearer (Polytron). Fine membrane particulates were pelleted by ultracentrifugation at 220,000g in a Ti-45 rotor for 60 min and pellets were topped with 100 mM NaCl, 20 mM Tris pH 7.5, 10 μM MTEP, 30% glycerol before flash-freezing in liquid nitrogen. Preparation of the MTEP-bound mGlu5 in nanodiscs. Crude membranes (described above) were thawed and solubilized in a buffer consisting of 750 mM NaCl, 20 mM HEPES pH 7.5, 1% DDM, 0.2% cholate, 0.12% CHS, 10 μM MTEP 49 , 160 μg ml −1 benzamidine and 2.5 μg ml −1 leupeptin (EMD Millipore). Solubilization proceeded for 90 min at 4 °C with constant stirring, and 1 mg ml
iodoacetamide was added to block reactive cysteines. Insoluble material was removed by centrifugation at 37,000g for 25 min, at which point 2 mM calcium and 4 ml M1 anti-Flag resin was added. Batch binding occurred for 90 min at 4 °C with constant stirring.
Resin was collected by centrifugation at 3,000g for 2 min, and washed in batch with 500 mM NaCl, 20 mM HEPES pH 7.5, 0.1% DDM, 0.01% CHS, 2 mM CaCl 2 and 10 μM MTEP. Resin was transferred to an EconoPac column and washed with the same buffer, and finally with 100 mM NaCl, 20 mM HEPES pH 7.5, 0.1% DDM, 0.01% CHS, 2 mM CaCl 2 and 10 μM MTEP. Protein was finally eluted using 100 mM NaCl, 20 mM HEPES pH 7.5, 0.1% DDM, 0.01% CHS, 10 μM MTEP, as well as 0.2 mg ml −1 Flag peptide and 5 mM EDTA. Fractions containing protein were pooled and concentrated to about 10 μM. Concentrated protein was reconstituted in MSP1D1 nanodiscs following previously published protocols 50 . In brief, mGlu5 was mixed with MSPD1 belt protein and lipids in the following ratio: 0.1 receptor:1 MSP1D1:65 POPC/POPG (POPC:POPG ratio 3:2). After 3 h of incubation on ice, Bio-Beads were added at a ratio of 1 mg Bio-Beads:14 mg lipid. After 1 h at 4 °C, the same amount of Bio-Beads were added again and reconstitution continued at 4 °C overnight with gentle rocking.
Reconstitution mixture was removed from beads, concentrated and injected on a Superose 6 10/30 gel-filtration column in 100 mM NaCl, 20 mM HEPES pH 7.5, 10 μM MTEP to separate aggregates and empty discs. Monomeric peak fractions were collected and concentrated to around 6 mg ml −1 for imaging. Preparation of mGlu5 bound to CDPPB, l-quisqualate and Nb43. Crude membranes (described above) were thawed and solubilized in a buffer consisting of 750 mM NaCl, 20 mM HEPES pH 7.5, 1% DDM, 0.2% cholate, 0.12% CHS, 10 μM MTEP, 160 μg ml −1 benzamidine and 2.5 μg ml −1
. Solubilization proceeded for 90 min at 4 °C with constant stirring, and 1 mg ml −1 iodoacetamide was added to block reactive cysteines. Insoluble material was removed by centrifugation at 37,000g for 25 min, at which point 2 mM calcium and 4 ml M1 anti-Flag resin was added. Batch binding occurred for 90 min at 4 °C with constant stirring.
Resin was collected by centrifugation at 3,000g for 2 min, and washed in batch with 500 mM NaCl, 20 mM HEPES pH 7.5, 0.1% DDM, 0.01% CHS, 2 mM CaCl 2 and 10 μM MTEP. Resin was transferred to an EconoPac column and washed with the same buffer. At this point, detergent was exchanged for glyco-diosgenin (GDN) by increasing the proportion of a 0.2% GDN/0.02% CHS mixture in stepwise increments and lowering the proportion of 0.1% DDM/0.01% CHS over a period of 30 min. The concentration of GDN was then lowered to 0.02% (around ten times the critical micelle concentration) in 100 mM NaCl, 20 mM HEPES, 0.02% CHS and 2 mM CaCl 2 , and then 5 μM CDPPB 51 was added to the wash buffer to exchange NAM for PAM. Ligand exchange was allowed to proceed for 20 min with buffer at 25 °C, at which point the receptor was eluted in 0.02% GDN, 0.002% CHS, 100 mM NaCl, 20 mM HEPES pH 7.5, 5 μM CDPPB supplemented with 5 mM EDTA and 0.2 mg ml −1 Flag peptide. Protein-containing fractions were pooled, concentrated and mixed with a 1.2 molar excess of Nb43 before injection on a Superose 6 10/30 gel-filtration column to remove excess nanobody and aggregate. Fractions containing both mGlu5 and Nb43 were pooled and concentrated to around 10-15 mg ml −1 for imaging. Cryo-EM data acquisition and processing. Inactive MTEP-bound mGlu5 (3.0 μl) in nanodiscs at a concentration of 6 mg ml −1 was applied to glow-discharged 200 mesh grids (Quantifoil R1.2/1.3), containing 0.0005% Amphipol A8-35 (Anatrace). A8-35 was included to aid sample vitrification, rather than an attempt to further reconstitute the receptor into amphipol. Excess sample was removed by blotting before plunge-freezing using a Vitrobot Mark IV (Thermo Fisher Scientific) at 4 °C and 100% humidity. Cryo-EM samples of mGlu5 in complex with Nb43, and mGlu5 in complex with Nb43 and l-quisqualate in GDN were prepared similarly with the addition of 0.1% octylglucoside (OG). Cryo-EM images were collected on a Titan Krios operated at 300 kV at a nominal magnification of 130,000× with a Gatan GIF Quantum LS Imaging energy filter using a Gatan K2 Summit direct electron camera in counting mode, corresponding to a pixel size of 1.06 Å. Each image was dose-fractionated over 40 frames with a dose rate of 7 electrons per pixel per second and total exposure time of 8 s, resulting in an accumulated dose of 50 electrons per Å 2 . The defocus range was set to 1.2-2.5 μm. The datasets of inactive mGlu5, inactive mGlu5 in complex with Nb43, and active mGlu5 in complex with Nb43 and l-quisqulate included 5,391, 7,414 and 1,984 micrographs, respectively. Dose-fractionated image stacks were subjected to beam-induced motion correction and dose-weighting using MotionCor2 52 . Contrast transfer function parameters for each micrograph were determined by Gctf v1.06 53 . Data processing of inactive mGlu5 was performed in RELION2.1 54 . A subset of 618,306 particle projections from well-defined averages was selected after two rounds of 2D reference-free classification starting with 1.6 million particles. This group was subjected to two rounds of 3D classifications with a pixel size of 2.12 Å. A selected subset of 123,096 projections was used to obtain the final map with RELION using a pixel size of 1.06 Å and C 2 symmetry imposed in the last rounds of refinement. This map has an indicated global resolution of 4.0 Å at a Fourier shell correlation (FSC) of 0.143. The dataset of mGlu5 in complex with Nb43 (inactive) was similarly processed in RELION, with a subset of 44,831 particle projections producing a map with indicated 7.9 Å resolution. The dataset of mGlu5 in complex with Nb43 and l-quisqualate (active) was preprocessed and sorted by 2D classification in RELION, resulting in 748,593 particles in welldefined averages. This subset of particle projections was exported to cryoSPARC 55 for further 2D and 3D classification. After two rounds of 3D classification in cryoSPARC, the angular and translational parameters for a selected group of 256,884 particles were imported to RELION for 3D classification without alignment. The final dataset of 73,472 particle projections was used in RELION to obtain a map with indicated global resolution of 4.0 Å. The final resolution estimate was based on the FSC between two unfiltered half-maps. Local resolution was determined using the Bsoft package 56 with unfiltered half-maps as input. Molecular dynamics simulations. The nanobody-VFT-domain complex and the VFT domain alone were prepared for molecular dynamics simulations with the Maestro software (Schrödinger) to add any missing side chains or hydrogens. Protonation state and hydrogen bonding were also optimized. VMD 57 was then used to generate input files for NAMD 58 with the OPLS-AA/M force field for proteins 59 . Implicit solvent molecular dynamics simulations were run with NAMD using the generalized Born method with an α-cutoff of 14 Å. Smoothing at 14 Å and a cutoff at 16 Å were applied to the nonbonded interactions. Temperature was maintained at 300 K with a Langevin thermostat using a damping coefficient of 1 ps
. A 1-fs time step was used with the SHAKE algorithm. Harmonic restraints were placed on all Cα before the system was minimized for 5,000 steps and gradually heated from 0 to 300 K in 20 K intervals ran for 50 ps each. Restraints were then removed and simulations were run for 25 ns. Four trajectories were run for each system with different initial random number seeds. The results of these replicates were used to obtain error bars for measured quantities. Molecular pharmacology methods. Constructs. The mGlu5 used for the studies consisted of the human mGlu5 with the signal peptide replaced by an extended HA-signal peptide and Flag-sequence (MKTIIALSYIFCLVFA-DYKDDDDAAA) before the mature mGlu5 sequence starting at amino acid Q21 (Uniprot P41594-2). Furthermore, part of the C terminus was removed by introducing a 6×His tag after amino acid L865. The mGlu5 construct (termed mGlu5-wt) was subcloned into pcDNA3.1(+)neo.
An ECD-truncated construct encoding the helical domain of mGlu5 was generated by introducing the HA-Flag tag and the first 20 residues of beta2AR in front of the mGlu5 helical domain from residues D565 to L865 followed by a 6×His tag. The constructs was subcloned into pcDNA3.1(+)neo and termed m5-HD. Introduction of the beta2AR residues rescued surface expression of the helical domain construct.
Receptor mutants were generated by site-directed mutagenesis or by overlap PCR using appropriate primers, restriction enzymes and subcloning of mutated PCR products. All constructs were sequence-verified. For the ECL2 truncation study the ECL2 residues I726-R727 (and S725-E728, P724-V729, D722-Y730) were removed by overlap PCR in full-length and ECD truncated constructs. For the TM6 mutational study the C129A, I791C, and C129A + I791C mutants were generated. Intracellular calcium release assay. The day before transfection, HEK293 cells (ATCC CRL-1573) were seeded at a density of 0.6 × 10 6 cells in T25 flasks and a volume of 4 ml growth medium. On the day of transfection, a mixture of 2.5 μg (high expression level) or 0.05 μg (low expression level) DNA encoding each of the receptor constructs, and 2 μg of EAAT3 encoding DNA, if indicated, was incubated with 8.5 μl FuGene6 (Promega, E2692) in a total of 150 μl OptiMEM (Gibco, 51985) for 20 min at room temperature and then added to the cells. The day after transfection cells were trypsinized and seeded in black-sided, clear-bottom poly-l-lysine-coated 96-well plates at a density of 50,000 cells per well.
On the day of assay (2 days after transfection), the (glutamate-containing) growth medium was replaced with HBSS buffer (HBSS Gibco 14025, 20 mM HEPES pH 7.5, 1 mM CaCl 2 , 1 mM MgCl 2 and 0.1% BSA) supplemented with BSA to 0.5% and left in the incubator at 37 °C for 4-6 h. Then cells were washed once in 100 μl HBSS buffer, and replaced with 100 μl of buffer containing Fluo-4, probenecid and 0.1% BSA (Fluo-4 Direct Calcium Assay Kit, Invitrogen, F10471). After 30 min incubation at 37 °C, intracellular calcium release upon receptor activation was initiated by addition of 50 μl ligand solutions in 3 times its final concentrations to each well and read using a FLIPR Tetra High Throughput Cellular Screening System (Molecular Devices). The maximum fluorescence response from each well was used in the data analysis. Data were fitted by nonlinear regression using GraphPad Prism. IP1 accumulation assay. HEK293 cells were transfected and seeded and to the point of assay initiation treated as described above except that cells were seeded in clear poly-l-lysine-coated 96-well plates. Following the wash, 50 μl HBSS buffer was added to each well. MPEP (Sigma, M5435) or buffer were preincubated by addition of MPEP or buffer in 50 μl HBSS buffer for 15 min at 37 °C before adding the orthosteric and/or allosteric activating ligands (or vehicle condition) also diluted in 50 μl HBSS buffer now supplemented with LiCl to a final concentration of 20 mM. After incubation for 30 min at 37 °C, the reaction was stopped by addition of 40 μl lysis buffer from the CisBio IP-One Tb HTRF Kit (CisBio, 62IPAPEC). The accumulated IP1 levels were then quantified according to the manufactures instructions and quantified using an Envision plate reader (Perkin Elmer). Data were calculated as the amount of IP1 formed per well or normalized to the basal IP1 level and fitted by nonlinear regression using GraphPad Prism. Radioligand binding ([ 3 H]l-quisqualic acid). HEK293 cells were transfected by adding 15 μg mGlu5-wt DNA and 38 μg polyethylenimine (from 2 mg ml −1 stock of Sigma-Aldrich, 408727) into a volume of 1 ml OptiMEM and incubating for 20 min at room temperature before adding the mixture to cells seeded at a density of 5 × 10 6 in 150 mm the day before transfection. Forty-eight hours after transfection cells were washed once and detached in DPBS supplemented with 2 mM EDTA. After pelleting, the cell pellet was resuspended in lysis buffer (50 mM HEPES pH 7.5 supplemented with cOmplete, EDTA-free Protease Inhibitor Cocktail (Roche, 30307800) and homogenized using a glass douncer. The lysate was spun at 1,500 r.p.m. at 4 °C for 10 min. The supernatant was then isolated and spun at 40,000g in SV-34 tubes for 20 min at 4 °C. The membrane pellet was resuspended in binding buffer (50 After shaking at 600 r.p.m. for 2 h at room temperature the receptor-bound radioligand was separated by filtration over Whatman GF/C unifilters (PerkinElmer, 6005174) using a 96-well FilterMate harvester (PerkinElmer). The filters were washed rapidly three times with a total of 2.5 ml of ice-cold binding buffer, and radioactivity was determined in a MicroBeta2 scintillation counter (PerkinElmer) after addition of 40 μl of MICROSCINT O (PerkinElmer, 6013611). Data were fitted by nonlinear regression using GraphPad Prism. Western blot. HEK293 cells were seeded and transfected in T25 flasks as described above using FuGene6. Immediately after transfection and the day following transfection, 10 μM MPEP or corresponding vehicle was added to the growth medium during expression. Forty-eight hours after transfections cells were washed once and detached in 1 ml DPBS supplemented with 2 mM EDTA. The cells were pelleted and resuspended in 100 μl lysis buffer (10 mM Tris, pH 7.5 supplemented with cOmplete, EDTA-free Protease Inhibitor Cocktail). Then cells were homogenized using a Precellys homogenizer and CK28 beads (Bertin Corp., 03961CK28) by homogenizing for 10 s at 5,000 r.p.m. and spinning of the lysate at 500g for 10 min to isolate the membrane-bound receptor. Equal amounts of receptor protein was resuspended in LDS buffer (LDS Sample Buffer, Non-Reducing (4X), Invitrogen, NP0007) supplemented with 8% SDS (Sigma, L3771) and loaded on a NuPAGE 3-8% Tris-acetate gel (Invitrogen, EA03752BOX). Protein was blotted onto PVDF membranes (Invitrogen, LC2005), and stained first with primary Flag-M2 antibody (Sigma F3165) followed by HPR-conjugated anti-mouse antibody (Thermo Scientific, 32430). Receptor monomers and dimers were detected and quantified using a chemiluminescent substrate and a ChemiDoc imaging system, followed by Imager Laboratory 6.0 software analysis (Bio-Rad). All cell lines were obtained directly from the manufacturer, but were not tested further for contamination nor re-authenticated by the authors. Reporting summary. Further information on experimental design is available in the Nature Research Reporting Summary linked to this article.
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All data generated or analyzed during this study are included in this published article and its Supplementary Information. The X-ray crystal structures and structure factors of the apo mGlu5 ECD, of the apo-mGlu5 ECD with Nb43, and of the mGlu5 ECD bound to Nb43 and L-quisqualate have been deposited in the Protein Data Bank under accession codes 6N4X, 6N4Y, and 6N50 respectively. Cryo-EM Maps of apo mGlu5 in nanodiscs, apo mGlu5 bound to Nb43 and active mGlu5 bound to Nb43 and L-quisqualate in GDN have been deposited in the Electron Microscopy Data Bank under accession codes 0346, 0347, and 0345 respectively. The atomic coordinates of apo mGlu5 and active mGlu5 bound to Nb43 and L-quisqualate have been deposited in the Protein Data Bank under accession codes 6N52 and 6N51 respectively.
Field-specific reporting Life sciences study design
All studies must disclose on these points even when the disclosure is negative.
Sample size
Sample sizes were not predetermined by statistical methods. For cryo-EM and crystallography data, sample sizes were determined by availability of microscope and X-ray synchrotron beam time, respectively. Crystallography data was sufficient to obtain >90% completeness at the highest resolution. Cryo-EM data was collected until we were able to refine a high-resolution structure that allowed us to obtain a highresolution reconstruction within the confines of limited microscope time. For signaling, we followed the standard practices in the field. In general, this consists of at least 3 independent experiments performed in triplicate. We believe this to be sufficient, and our estimates of the mean and SEM did not deviate by incorporating more experiments.
Data exclusions No data was systematically excluded. The process of generating 3D maps from cryo-EM particles involves sorting for particles that are damaged, have low signal, or are in minority conformations that are unlikely to refine correctly. This is implemented in Relion 2.1 and cryoSparc and is standard in the field. There was, however, no pre-determined criteria for exclusion of particles.
Replication
All attempts at replication succeeded. In general, our data shows mean +/-SEM from 3-6 independent experiments (biological replicates, n) performed in duplicate or triplicate (technical replicates of the biological replicates). Figure 1b shows individual data points from a representative experiment (of 3 independent experiments in triplicate). The western blotting data shows lanes from at least 3 independent transfections. There was no attempt to replicate cryo-EM data. This data involves averaging of tens of thousands of particles.
Randomization Randomization was not attempted nor necessary for this study. This was not a clinical trial or animal study that is dependent on randomization. All variables could be controlled.
Blinding
Blinding was not attempted or needed. There was no group allocation performed in this study.
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